美国国立卫生研究院卒中量表:缺血性卒中急性治疗试验的替代主要结局指标
该研究利用MR CLEAN和IMS III两项血管内治疗试验数据,采用因果中介模型分析NIHSS(24小时及5-7天)与3个月mRS的关系。结果显示NIHSS与mRS显著相关,且治疗效应大部分由NIHSS中介,支持NIHSS作为急性缺血性卒中试验的替代主要结局,尤其适用于II(b)期试验。
要点
- NIHSS在24小时和5-7天与3个月mRS显著相关。
- 血管内治疗对mRS的效应大部分由早期NIHSS中介。
- NIHSS可作为急性缺血性卒中试验的替代主要结局,尤其II(b)期。
核心结论
- 治疗1周内的NIHSS满足替代终点要求,可作为急性缺血性卒中试验的主要结局指标,尤其适用于II(b)期试验。
研究设计与样本
- 基于MR CLEAN(N=500)和IMS III(N=656)两项血管内治疗随机对照试验数据的因果中介分析,采用线性及有序logistic回归校正混杂因素。
主要发现
- 两项试验中NIHSS(24小时和5-7天)与3个月mRS均显著相关。
- MR CLEAN中血管内治疗对mRS的效应经24小时和5-7天NIHSS校正后,共同比值比从1.68(95%CI 1.22-2.32)分别降至1.36(95%CI 0.97-1.91)和1.24(95%CI 0.87-1.79),提示治疗效应大部分由NIHSS中介。
- IMS III中血管内治疗对24小时和5-7天NIHSS无效应,与对mRS无效应一致。
关键数值与推荐
- NIHSS评估前死亡的患者赋最大分值42分,NIHSS+1后经log10转换。
- MR CLEAN中血管内治疗对mRS的共同比值比为1.68(95%CI 1.22-2.32)。
临床怎么用
- 在急性缺血性卒中试验中,可考虑采用治疗1周内的NIHSS作为主要结局指标,以减少评估项目、缩短试验周期并降低成本。
局限性
- 是否及在何种条件下可用于III期试验尚需领域内各方讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The modified Rankin Scale (mRS) at 3 months is the most commonly used primary outcome measure in stroke treatment trials, but it lacks specificity and requires long-term follow-up interviews, which consume time and resources. An alternative may be the National Institutes of Health Stroke Scale (NIHSS), early after stroke. Our aim was to evaluate whether the NIHSS assessed within 1 week after treatment could serve as a primary outcome measure for trials of acute treatment for ischemic stroke. Methods- We used data from 2 randomized controlled trials of endovascular treatment for ischemic stroke: the positive MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; N=500) and the neutral IMS (Interventional Management of Stroke) III trial (N=656). We used a causal mediation model, with linear and ordinal logistic regression adjusted for confounders, to evaluate the NIHSS 24 hours and 5 to 7 days after endovascular treatment as primary outcome measures (instead of the mRS at 3 months) in both trials. Patients who had died before the NIHSS was assessed received the maximum score of 42. NIHSS+1 was then log10-transformed. Results- In both trials, there was a significant correlation between the NIHSS at 24 hours and 5 to 7 days and the mRS. In MR CLEAN, we found a significant effect of endovascular treatment on the mRS and on the NIHSS at 24 hours and 5 to 7 days. After adjustment for NIHSS at 24 hours and 5 to 7 days, the effect of endovascular treatment on the mRS decreased from common odds ratio 1.68 (95% CI, 1.22-2.32) to respectively 1.36 (95% CI, 0.97-1.91) and 1.24 (95% CI, 0.87-1.79), indicating that treatment effect on the mRS is in large part mediated by the NIHSS. In the IMS III trial there was no treatment effect on the NIHSS at 24 hours and 5 to 7 days, corresponding with the absence of a treatment effect on the mRS. Conclusions- The NIHSS within 1 week satisfies the requirements for a surrogate end point and may be used as a primary outcome measure in trials of acute treatment for ischemic stroke, particularly in phase II(b) trials. This could reduce stroke-outcome assessment to its essentials (ie, neurological deficit), and reduce trial duration and costs. Whether and under which conditions it could be used in phase III trials requires a debate in the field with all parties. Clinical Trial Registration- URL: http://www.isrctn.com. Unique identifier: ISRCTN10888758; https://www.clinicaltrials.gov. Unique identifier: NCT00359424.
引用
- Chalos V, van der Ende NAM, Lingsma HF, et al. National Institutes of Health Stroke Scale: An Alternative Primary Outcome Measure for Trials of Acute Treatment for Ischemic Stroke. Stroke. 2019. PMID: 31795895. doi:10.1161/STROKEAHA.119.026791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。